

**Remarks**

Currently, claims 1-3, 5, 7, 12 and 15 are pending. Claims 1, 5, 7 and 15 have been amended. Claims 4, 6, and 9-11 have been cancelled. Claims 8 and 16-20 have been withdrawn subject to a restriction requirement. No new matter is added.

**1. Claim Rejection Under 35 USC 102, first paragraph**

Claims 6 and 7 are rejected under 35 USC 112, first paragraph, because the specification, while being enabling for a compound of formula (I) or pharmaceutically acceptable salts of said compound does not reasonably provide enablement for a solvate of a compound of formula (I).

Applicants have now mooted this rejection by removing the term solvate from claims 6 and 7.

**a. Claim Objection-Non Elected Subject Matter**

Claims 4-6 and 15 were objected to as containing non-elected subject matter. Likewise, claims 1-7, 12, 14 and 15 were objected to because claim 1 contained proviso language that was not related to applicants' elected subject matter.

Applicants have now mooted this rejection by removing the proviso language from claim 1, canceling claims 4 and 6, and amending claims 5 and 15.

Applicants believe the present claims are in condition for allowance and such action is respectfully requested. If the Examiner has any outstanding issues with the pending claims, he is encouraged to telephone the undersigned at (919) 483-8406 for expeditious handling.

Respectfully submitted,



Robert (Steve) Thomas  
Attorney for Applicants  
Registration No. 52,284

Date: 3/5/2009  
Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8406  
Facsimile: (919) 483-7988